Latest News from Origin
ViaNautis Bio – $25m investment round
Existing Origin portfolio company ViaNautis Bio (formerly SomaServe) has secured $25m in additional finance to further develop and commercialise therapies exploiting its proprietary polyNaut® drug delivery platform. The round was lead by new institutional and corporate venture investors but included significant participation from existing shareholders, including Origin.
Read more here.
